F-box proteins in cancer stemness: An emerging prognostic and therapeutic target.
Cancer pathogenesis
Cancer stem cells
F-box proteins and signaling
Poor clinical outcomes
Stemness
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
04
05
2021
revised:
16
06
2021
accepted:
05
07
2021
pubmed:
16
7
2021
medline:
17
3
2022
entrez:
15
7
2021
Statut:
ppublish
Résumé
Cancer is a complex heterogenic disease with significant therapeutic challenges. The presence of cancer stem cells (CSCs) in cancer tissue orchestrates tumor growth, progression, and metastasis, the tumor heterogeneity, disease relapse, and therapeutic resistance. Hence, it is imperative to explore how progenitor or cancer-initiating cells acquire stemness features and reprogram different biological mechanisms to maintain their sustained oncogenicity. Interestingly, deregulation of F-box proteins (FBPs) is crucial for cancer stemness features, including drug resistance and disease relapse. In this review, we highlight recent updates on the clinical significance of targeting FBPs in cancer therapy, with emphasis on eliminating CSCs and associated therapeutic challenges. Moreover, we also discuss novel strategies for the selective elimination of CSCs by targeting FBPs.
Identifiants
pubmed: 34265459
pii: S1359-6446(21)00314-7
doi: 10.1016/j.drudis.2021.07.006
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
F-Box Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2905-2914Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.